Dr. G. Bozet, MD, Author At PanNASH

NASH Observatory Commented Articles Definitions Articles

NAFLD as a metabolic disease, a review

A systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of NAFLD as a metabolic disorder was performed by B. Cariou et al. (Inserm, CNRS, France). It appears that here is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction...

July 29, 2021

Management Articles Commented Articles NASH Observatory Ppar Articles

Pharmacotherapy in NAFLD/NASH

This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....

July 26, 2021

NASH Observatory Commented Articles Epidemiology Articles

Ethnicity and diversity in NAFLD

Globally, the rise in prevalence of obesity and metabolic syndrome as a whole has been linked to increased access to processed foods, such as refined sugars and saturated fats. Consequently, NAFLD is on the rise in both developed and developing nations.
This review by MAT Han et al...

July 21, 2021

Management Articles Commented Articles Comorbidities Articles NASH Observatory

European NAFLD guidelines: limitations when applied to T2D patients

G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...

July 14, 2021

NASH Observatory Commented Articles Comorbidities Articles

Pulmonary hypertension and incidence of NAFLD: a retrospective study

In this retrospective cohort study of 18,910 patients, M. S. Jördens et al. examine a potential association between pulmonary hypertension and NAFLD and liver cirrhosis in an outpatient cohort in Germany. Their data suggests that incidence rates of NAFLD of NAFLD are significantly higher among patients with pulmonary ...

July 12, 2021

NASH Observatory Commented Articles Pathophysiology Articles

From NAFLD/NASH to HCC: role of mitochondrial defects

This review by M. Longo et al. (IRCCS – Università degli Studi di Milano, Italy) discusses how mitochondrial defects may be translated into causative explanations of NAFLD-driven hepatocellular carcinoma. Acting as central metabolic hubs, the mitochondria rapidly adapt to different metabolic alterations...

July 5, 2021

NASH Observatory Commented Articles Epidemiology Articles

Increasing prevalence of NAFLD/NASH among children, adolescents, and young adults

X. Zhang et al. (Fudan University, Shanghai, China) collected, from the Global Burden of Disease database, annual cases, and prevalence of NAFLD/NASH from 1990 to 2017, by sex, region and country. This study shows that both the prevalence and number of cases of NAFLD/NASH have...

June 30, 2021

Management Articles Commented Articles NASH Observatory Pathophysiology Articles

NAFLD/NASH-related liver fibrosis: mechanisms, treatment, and prevention

NAFLD or NASH are nowadays the leading causes of hepatic fibrosis worldwide. In their review, F. Tacke (Charité University Medicine, Berlin, Germany) and R. Weiskirchen (RWTH University Hospital, Aachen, Germany) discuss recent advances in antifibrotic prevention and therapy....

June 28, 2021

NASH Observatory Commented Articles Epidemiology Articles

Burden of NAFLD in Canada

M. G. Swain et al. (University of Calgary, Canada) used a Markov model to forecast the burden of disease of NAFLD and NASH among Canadians with NAFLD from 2019 to 2030. The model projected that the number of NAFLD cases would increase by 20% between 2019 and 2030. Increasing rates of obesity ...

June 24, 2021

Management Articles Commented Articles NASH Observatory

Immunotherapy-treated HCC: NASH limits anti-tumour surveillance

Immunotherapy has been approved for treating hepatocellular carcinoma (HCC), but biomarker-based stratification of patients for optimal response to therapy is an unmet need. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) did not lead...

June 21, 2021

NASH Observatory Commented Articles

NAFLD and risk factors: accuracy and limitations of the ICD-10-Australian Modification

Understanding the limitations of International Classification of Diseases (ICD) codes is important to improve the reliability of health system databases for epidemiological studies and health services research. KL Hayward et al. conducted a retrospective audit to explore the accuracy and limitations of the ICD-10-Australian Modification...

June 16, 2021

NASH Observatory Commented Articles

NAFLD in childhood obesity

NAFLD in children and adolescents has an estimated prevalence of 36.1% in the context of obesity. NAFLD in childhood persisting into adulthood is likely to be harmful. Early disease detection is required. Healthy eating and physical activity, remain the only prevention and treatment strategies for paediatric NAFLD. This review discusses...

June 14, 2021